PPT-End-points utilized in breast cancer

clinical trials Discussion Novartis Oncology Discussant Arunava Chakravartty Stat4Onc Symposium Hartford CT Apr26 2019 Disclaimer All views expressed in the slide represent the individual views of the presenter and should not be seen as representing the views of Novartis its board or its shareholders. What’s New to Know?. The Issue of Breast Density. Catherine Babcook MD. Partner, Mountain Medical Physician Specialists. Medical Director of Breast Imaging McKay Dee Hospital Center. Disclosure. This presentation has no commercial content, promotes no commercial vendor and is not supported financially by any commercial vendor. I receive no financial remuneration from any commercial vendor related to this presentation.. DR. A. AKHATOR FWACS, FICS. SENIOR LECTURER DELSU . CONSULTANT SURGEON DELSUTH. PRE-TEST. Breast cancer is the most common cancer in women in Nigeria . Breast cancer is the most common cause of cancer related deaths. Diana Sarfati. Director, Cancer Control and Screening Research Group. Breast cancer. Most common cancer for women in NZ . 600 women die each year from breast cancer. Trends . in age standardized I. ncidence . Changing Philosophies in Educating Women and Teens . Courtney Benedict CNM MSN. Disclosures. Merck Nexplanon trainer . Session Objectives. Explain the rationale for initiation and frequency of clinical breast exams to clients. SWAG Site Specific Group. Maxine Taylor. Senior Research Delivery Manager - Cancer. Friday 1. st. July . 2016. Clinical Research Network. West of England. South West Research Networks & SWAG. West of England. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. The Obstetrics & Gynecological Society of Bhopal. &. AMPOGS . Research Public Welfare Society. Screening tools. Clinical Breast examination. Breast self examination. Mammography. Ultrasonography/. Susan M. Domchek, MD. Basser Professor of Oncology. University of Pennsylvania . Sex. Age. Family . history. Depends on specific of family history. Depends on whether there is a k. nown . genetic . susceptibility. Dr. Ruth . Heisey. Family Physician/GP Oncologist. Women’s College Hospital/Princess Margaret . Cancer Centre. Clinician Investigator/Associate Professor. University of Toronto. Sandy Fawcett . RN(EC) NP-Adult. Generosa. . Grana. , MD. Professor, Cooper Medical School of Rowan University. Director, MD Anderson Cancer Center at Cooper. Overview. Factors that affect breast cancer risk. Tools to assess risk. Role of genetics in this process. For Fellows November 2016. American Cancer Society, 2015 Statistics. Risk Factors. Female. Age: median 57-62. Family history. Previous biopsies. Atypical changes. BRCA positive. Hormone replacement. Alcohol use. HR Advanced Breast Cancer:. Introduction. Case Study Discussion. Case Study Discussion (cont). ASCO Key Guideline Recommendations for HR MBC. ASCO Key Guideline Recommendations for HR MBC (cont). SWOG 0226 Study: Anastrozole Alone vs Anastrozole Fulvestrant in HR Breast Cancer . March 2019. Preview/Introduction. The Risk of Breast Cancer to Women. Does Mammography Save Lives?. When to Start and How Often Should Women Screen?. Risks Versus Benefits of Mammography. Breast Cancer: The Impact on Women.  breast tissue, . most . commonly from the inner lining . of.  milk ducts or the lobules that supply the . ducts . with . milk.. Breast cancer may be invasive or noninvasive. . Invasive.